CY2373B1 - Pharmaceutical composition comprising a proteinaseinhibitor and a monoglyceride. - Google Patents

Pharmaceutical composition comprising a proteinaseinhibitor and a monoglyceride.

Info

Publication number
CY2373B1
CY2373B1 CY0300057A CY0300057A CY2373B1 CY 2373 B1 CY2373 B1 CY 2373B1 CY 0300057 A CY0300057 A CY 0300057A CY 0300057 A CY0300057 A CY 0300057A CY 2373 B1 CY2373 B1 CY 2373B1
Authority
CY
Cyprus
Prior art keywords
proteinaseinhibitor
monoglyceride
pharmaceutical composition
compositions
monoglycerides
Prior art date
Application number
CY0300057A
Other languages
English (en)
Inventor
Carole Anne Bailey
Josephine Christine Ferdinando
Navnit Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CY2373B1 publication Critical patent/CY2373B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CY0300057A 1995-06-06 2003-08-22 Pharmaceutical composition comprising a proteinaseinhibitor and a monoglyceride. CY2373B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors

Publications (1)

Publication Number Publication Date
CY2373B1 true CY2373B1 (en) 2004-06-04

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0300057A CY2373B1 (en) 1995-06-06 2003-08-22 Pharmaceutical composition comprising a proteinaseinhibitor and a monoglyceride.

Country Status (27)

Country Link
EP (1) EP0831826B1 (de)
JP (1) JP3238412B2 (de)
CN (1) CN1092960C (de)
AT (1) ATE226075T1 (de)
AU (1) AU709796B2 (de)
BG (1) BG63711B1 (de)
BR (1) BR9610842A (de)
CA (1) CA2224125C (de)
CY (1) CY2373B1 (de)
CZ (1) CZ292192B6 (de)
DE (1) DE69624354T2 (de)
DK (1) DK0831826T3 (de)
EA (1) EA001413B1 (de)
ES (1) ES2182996T3 (de)
HK (1) HK1010136A1 (de)
HU (1) HU223899B1 (de)
IL (1) IL122353A0 (de)
IS (1) IS2661B (de)
MX (1) MX9709193A (de)
NO (1) NO324531B1 (de)
NZ (1) NZ311646A (de)
OA (1) OA10546A (de)
PL (1) PL184820B1 (de)
PT (1) PT831826E (de)
SK (1) SK282121B6 (de)
TR (1) TR199701541T1 (de)
WO (1) WO1996039142A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225174T1 (de) 1997-07-29 2002-10-15 Upjohn Co Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
DE69804624T2 (de) 1997-07-29 2002-09-19 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
NZ513441A (en) * 1999-02-08 2004-01-30 Alza Corp Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2108705A1 (de) 2008-04-08 2009-10-14 Universität Duisburg-Essen Verfahren zur Analyse der epigenetischen Lage des HtrA1 Gens in einer biologischen Probe
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
BG102106A (en) 1998-08-31
AU709796B2 (en) 1999-09-09
DE69624354T2 (de) 2003-06-05
PL184820B1 (pl) 2002-12-31
ES2182996T3 (es) 2003-03-16
WO1996039142A1 (en) 1996-12-12
EP0831826B1 (de) 2002-10-16
CN1092960C (zh) 2002-10-23
EA001413B1 (ru) 2001-02-26
NO975665L (no) 1998-02-05
HUP9801905A3 (en) 2001-04-28
NO975665D0 (no) 1997-12-05
EA199800023A1 (ru) 1998-08-27
CA2224125C (en) 2004-09-28
MX9709193A (es) 1998-03-31
AU6300496A (en) 1996-12-24
TR199701541T1 (xx) 1998-03-21
NO324531B1 (no) 2007-11-12
IL122353A0 (en) 1998-04-05
NZ311646A (en) 2000-02-28
ATE226075T1 (de) 2002-11-15
JP3238412B2 (ja) 2001-12-17
CZ380397A3 (cs) 1998-03-18
HK1010136A1 (en) 1999-06-17
CZ292192B6 (cs) 2003-08-13
IS2661B (is) 2010-08-15
CA2224125A1 (en) 1996-12-12
JPH10507202A (ja) 1998-07-14
PL323860A1 (en) 1998-04-27
BG63711B1 (bg) 2002-10-31
EP0831826A1 (de) 1998-04-01
CN1186434A (zh) 1998-07-01
PT831826E (pt) 2003-02-28
HUP9801905A2 (hu) 1999-05-28
DK0831826T3 (da) 2003-02-03
SK162797A3 (en) 1998-05-06
HU223899B1 (hu) 2005-03-29
DE69624354D1 (de) 2002-11-21
OA10546A (en) 2002-05-29
BR9610842A (pt) 1999-07-13
SK282121B6 (sk) 2001-11-06
IS4627A (is) 1997-12-04

Similar Documents

Publication Publication Date Title
CY2373B1 (en) Pharmaceutical composition comprising a proteinaseinhibitor and a monoglyceride.
NL301005I1 (de)
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
MY116525A (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
AU6453794A (en) Simultaneous amplification of multiple targets
HK1027748A1 (en) Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glcia glaucoma
AU1390199A (en) Compositions and methods for inhibiting the activity of certain genes
IL117247A (en) Pharmaceutical compositions comprising protease inhibitors and quinoxalines
IL122942A0 (en) Esters of 1-beta-d-arabinofuranosylcytosine and pharmaceutical compositions containing them
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
IL148003A0 (en) Floating pharmaceutical composition comprising an active phase and a non-active phase
ZA963397B (en) Esters and pharmaceutical compositions
EP1030661A4 (de) N,n-diethylglycolamidoester des indols als medikamentvorstufen von spla 2 inhibitoren
AU8921298A (en) Inhibitors of prenyl-protein transferase
ZA9811574B (en) Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative.
AU6016496A (en) Antianginal drug comprising nitroxy derivative as active ingredient
ZA964925B (en) Pharmaceutical compositions for gene therapy.
GB9513399D0 (en) Improved pharmaceutical compositions for gene therapy
GB9519304D0 (en) Improved pharmaceutical compositions for gene therapy
IL117302A0 (en) Cryptophycin derivatives methods for the production thereof and pharmaceutical compositions containing the same
ZA966973B (en) Packs for atircles of merchandise.